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Abstract
Purpose Cancer pain is a multidimensional experience that
includes physiological, sensory, affective, cognitive, behav-
ioral, and sociocultural dimensions. Few prospective studies
have examined the relationship between a patient’s expecta-
tion of pain improvement and the pain prognosis. The aim of
this prospective study was to investigate whether patients’
expectation to pain reduction was associated with pain inten-
sity after morphine treatment in opioid treatment-naïve pa-
tients with various types of cancer.
Methods The subjects were patients scheduled for cancer pain
treatment with morphine who were taking nonsteroidal anti-in-
flammatory drugs daily. Morphine treatment was performed ac-
cording to the standard method, including titration (NCCN
Guidelines™, Adult Cancer Pain). Simple regression analysis
was performed between pain intensity numerical rating scale
(NRS) (day 8) as the dependent variable, expectation of pain
decrease NRS (day 1), tumor types, and the following covariates
as independent variables: patients’ characteristics such as age,
gender, PS (day 1), genotype of catechol-O-methyltransferase,
total scores of Hospital Anxiety and Depression Scale (day 1),
and pain intensity NRS (day 1). Multiple regression analysis
was performed using forced entry methods with pain intensity
NRS (day 8) as the dependent variable, and expectation of pain
decrease NRS (day 1) and the covariates as independent vari-
ables that had a p value <0.05 in the simple regression models.
Results A total of 100 patients with baseline data were includ-
ed, and 97 patients (51% female) met the inclusion criteria.
Patients with a high expectation of pain decrease NRS had a
significantly lower pain intensity NRS (day 8) (p = 0.001).
Conclusion Non-pharmacological factors such as expecta-
tions for pain treatment could also be important factors to treat
cancer pain, which might be associated with communication
skills in physicians.
Keywords Cancer pain . Expectation in pain decrease .
Morphine treatment . Psycho-oncology
Introduction
Pain is a common symptom in cancer patients [1, 2] that in-
creases in prevalence and intensity with disease progression
[3, 4] and influences multiple domains of quality of life [5–8].
Ahles et al. [9] and McGuire et al. [10] have described cancer
pain as a multidimensional experience, including physiologic,
sensory, affective, cognitive, behavioral, and sociocultural
dimensions.
There is a need for a multifaceted approach to non-cancer
chronic pain that includes the effects of catastrophizing (ex-
aggeration of pain) [11] and expectation of pain improvement
[12, 13]. These factors are related to pain severity, disorder,
and prognosis and provide important information for psycho-
somatic treatment of non-cancer chronic pain [14]. Studies in
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patients with whiplash injury due to traffic accidents and in
those with back pain have shown positive correlations be-
tween expectation of pain improvement and a decrease in
actual pain [12, 13]. There are several studies investigating
the effect of expectation as a predictor for pain level in patients
with non-specific low back pain and total joint arthroplasty
[15, 16], and according to the systematic review, 15 of the 16
studies showed that positive expectations were associated
with better health outcomes including pain [17].
Furthermore, almost all guidelines have mentioned the im-
portance not only the use of pharmacological therapy (espe-
cially in chronic opioid therapy) but also the non-
pharmacological therapy including reduction of pain
catastrophizing and rise of expectation of patients in chronic
non-cancer pain because safe and effective chronic opioid
therapy for chronic non-cancer pain requires clinical skills
and knowledge in both the principles of opioid prescribing
and on the assessment and management of risks associated
with opioid abuse, addiction, and diversion [18, 19].
On the other hand, in treating cancer patients, the main
approaches to cancer pain (= physical pain) are drug ther-
apies, such as non-steroidal anti-inflammatory drugs
(NSAIDs) and opioids. Since the report is less about the
importance of non-drug therapies (for example, interview
that give hope to the patient), which are often frequently
used in chronic pain models of non-cancer, results and
guidelines of non-cancer patients study [18, 19] might
not be used as they are. Knowing expectation influence
on the pain prognosis, we believe that personalized med-
icine, which predicted the pain prognosis, might be spread
in the field of treatment of cancer pain. It may also be
possible to treat cancer patients of chemical coping, which
has recently become a problem [20–22].
However, there are few studies on expectation of symptom
improvement before treatment in cancer patients [23], and the
relationship between a patient’s expectation of pain improvement
and the pain prognosis has not been examined in cancer patients.
In this prospective study, we investigated whether patients’
expectation to pain reduction was associated with pain inten-
sity after morphine treatment in a cohort of opioid treatment-
naïve patients with various types of cancer.
Materials and Methods
Patients and Samples
This prospective study was conducted from 2009 to 2012 at
the Kindai University Faculty ofMedicine and Sakai Hospital.
A total of 100 patients with opioid treatment-naïve and histo-
logically confirmed malignant neoplasms who were sched-
uled to undergo opioid treatment were evaluated in the study.
They were recruited and selected by non-probabilistic conve-
nience sampling by their physician’s selections from the out-
patient and inpatient service of Department of Medical
Oncology. Of these patients, 97 met inclusion criteria of
≥18 years of age, a verified cancer diagnosis, cancer pain
suitable for morphine treatment (excluding neuropathic pain,
predominant incidental pain, glomerular filtration rate <30 ml/
min, no history of opioid/drug abuse or alcoholism from self-
reported questionnaire), daily use of non-steroidal anti-inflam-
matory drugs, and ability to give signed informed consent.
Three patients were ineligible, 1 patient did not meet inclusion
criteria, 1 patient was due to medical event, and 1 patient
withdrew consent. All 97 patients underwent gene expression
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Fig. 1 Flowchart of the study. A total of 100 patients with baseline data
were included, 3 patients were ineligible, 1 patient did not meet inclusion
criteria, 1 patient was due to medical event, and 1 patient withdrew
consent. All 97 patients underwent gene expression analysis. Ninety-
one patients were evaluated in genotype analysis. The required dose of
morphine (day 8) was evaluated in 85 patients. Assessments were
conducted day 1 (pre-treatment) and on day 8 (8 week after treatment).
NSAIDs non-steroidal anti-inflammatory drugs, NRS Numerical Rating
Scale, SNPs single nucleotide polymorphisms, COMT catechol-O-
methyltransferase
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analysis because the DNA samples were insufficient in 6
cases. The required dose of morphine (day 8) was evaluated
in 85 patients, excluding 12 who could not continuously re-
ceive morphine due to adverse effects or death (Fig. 1).
Clinical features including age, sex, Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus (PS), and types of primary malignant neoplasm were
recorded. Morphine treatment was performed according
to the standard method, including titration (NCCN
Guidelines™, Adult Cancer Pain) by specialized pallia-
tive care doctors. On this step, they explained standard-
ized information about potential benefits and adverse
effects to their patients. Assessments were conducted
pre-treatment (day 1) and 1 week after treatment (day
8).
This study was approved by the Regional Committee for
Medical Research Ethics, Kindai University Faculty of
Medicine and informed consent was obtained from all indi-
vidual participants included in the study.
Measures
Pain Score
Pain score was assessed with 0–10 Numerical Rating Scale
(NRS, 0 = no pain to 10 = the worst imaginable pain) (pain
intensity NRS) on day 1 (pre-treatment) and on day 8 (1 week
after treatment) by asking patients by the following question;
BHow intense was your average pain for the past 24 hours?^
Patient’s Expectation of a Decrease in Pain
Patients’ expectation of a decrease in pain determined
via a questionnaire with a 0–10 NRS (0 = no improve-
ment to 10 = full improvement) on day 1 (pre-
treatment) (expectation of pain decrease NRS (day 1))
and on day 8 (1 week after treatment). Nurses who
were not related to this study handed questionnaires to
patients. The questionnaire had the following question;
BHow much do you think your pain will get better?^
The questionnaire was self-administered.
Hospital Anxiety and Depression Scale
To assess correlations with pain intensity NRS (day 1 and day
8), anxiety/depression before treatment (day 1) and on day 8
was evaluated using the Hospital Anxiety and Depression
Scale (HADS). In accordance with a systematic review by
Cosco et al. [24], we use HADS total scale rather than the
subscales.
Genotyping
The single nucleotide polymorphisms (SNPs) of catechol-O-
methyltransferase (COMT) 472G→A (rs4680, p.Val158Met)
alsomodulate the genetic response to opioid medications [25].
We performed an exploratory study in the first half of 50 cases
at the beginning. To find predictive biomarkers of the treat-
ment outcome of morphine, we performed a functional geno-
type analysis of OPRM1 118A→G (rs1799971, p.Asn40Asp)
and COMT 472G→A (rs4680, p.Val158Met). The treatment
outcome of morphine was examined based on the plasma
concentration of morphine and the required dose according
to genotype on days 1, 2, and 8 [26]. On day 1, blood sample
for genotyping was conducted, and measures (pain score,
HADS, and patients’ expectation) were conducted on day 1
(before and post treatment), day 2, and day 8. After that, we
performed a confirmatory study in the second half of 50 cases.
At this time, we measured only COMT, which was a signifi-
cant difference in the exploratory study. Since this was not
related to the results of the present study and we performed
same psychological measures, we have decided to treat all
patients as one group and omit details on day 1 (post treat-
ment), day 2, and blood sampling except COMT genotypes on
the Fig. 1 in order to avoid confusion.
Genomic DNA isolated from blood samples using a
QIAamp® DNA Blood Mini Kit (Qiagen) was amplified
with the following primers: COMT forward, 5′-GAT
TCA GGA GCA CCA GCC CTC C-3′ and reverse
(intronic), 5′-CAC TGA GGG GCC TGG TGA TAG
TG-3′. PCR was performed in a 20-μl volume containing
20 ng of template, 0.5 μM of each primer, Ampdirect
Plus (Shimadzu Corp., Kyoto, Japan), and 0.5 units of
NovaTaq™ DNA Polymerase (Merck, Darmstadt,
Germany). Amplification was performed for 35 cycles
(95 °C for 30 s, 60 °C for 30 s, and 72 °C for 45 s).
The resulting PCR fragments consisting of 210 bp
(COMT) were directly sequenced with the corresponding
forward and reverse primers, respectively [26].
Statistical Analysis
All data are expressed as mean ± standard deviation.
We first undertook a bivariate relationship using linear
regression analysis between pain intensity NRS (day 8)
as the dependent variable and expectation of pain de-
crease NRS (day 1) and the following covariates as an
independent variable: patients’ characteristics such as
age, gender, PS (day 1), genotype of COMT, pain in-
tensity NRS (day 1), and total scores of HADS (day 1).
We also tested the association between pain intensity
NRS (day 8) and cancer types (pancreatic cancer or
not) because pancreatic cancer patients had significantly
lower expectation of pain decrease NRS (day1) than the
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other cancer patients. Then, multiple linear regression
analysis was performed using forced entry methods with
pain intensity NRS (day 8) as the dependent variable
and expectation of pain decrease NRS (day 1) and the
covariates as independent variables that had a p value
<0.05 in simple linear regression analysis, which means
Table 1 Clinical characteristics
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NRS mean (SD) Day 1 (before treatment) 6.83 (2.22)
Day 8 3.53 (2.49)
HADS total scores (SD) Day 1 (before treatment) 15.28 (7.91)
Day 8 14.89 (7.73)
Expectation of pain decrease Day 1 (before treatment) 6.70 (2.59)
N.E. not evaluated
Table 2 Independent determinants of pain on day 8
Item Simple regression model Multiple regression model (R2 = 0.28)
β t value Partial regression
coefficient (95% CI)
p value β t value Partial regression
coefficient (95% CI)
p value VIF
Age −0.07 −0.61 −0.17 (−0.07 to 0.04) 0.54
Gender 0.04 0.36 0.20 (−0.92 to 1.32) 0.72
Genotype 0.02 0.14 0.08 (−1.04 to 1.20) 0.89
PS (day 1) −0.31 −2.89 −1.04 (−1.75 to −0.32) 0.005* −0.35 −3.40 −1.18 (−1.88 to −0.49) 0.001 1.00
Tumor types 0.01 0.10 0.15 (−2.79 to 3.08 0.92
HADS (day 1) 0.22 1.96 0.11 (−0.11 to 0.22) 0.05
Expectation of pain decrease (day 1) −0.39 −2.78 −0.32 (−0.53 to −0.12) 0.003* −0.36 −3.50 −0.34 (−0.54 to −0.15) 0.001 1.00
NRS (day 1) 0.21 1.88 0.23 (−0.13 to 0.48) 0.06
β standardized partial regression coefficient, VIF variance inflation factors
*p < 0.00625 was statistically significant using Bonferroni correction for multiple tests
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that the required level for p values was <0.00625 with
Bonferroni correction for multiple tests in eight simple
regression models. A two-sided significance level of
0.05 was used for multiple regression analysis. All sta-
tistical analyses were performed using SPSS software
(version 19.0; SPSS Japan Inc., Tokyo).
Results
Characteristics of the Patients
The characteristics of the 97 patients (48 males, 49 females)
are shown in Table 1. The median age was 69 years (40–
85 years). There were 58 inpatients and 39 outpatients. The
primary tumors were lung cancer in 39 patients (40%), colo-
rectal cancer in 13, breast cancer in 12, gastric cancer in 8,
pancreatic cancer in 5, gallbladder cancer in 4, and cancer of
unknown primary cause in 4. More than 90% of the subjects
had metastasis and 79% had a PS of 0 to 2. The median
required doses of morphine were 30 mg on day 1 (Table 1).
Factors Influencing Pain Intensity NRS (Day 8)
With regard to simple regression analysis with pain intensity
NRS (day 8) as the dependent variable, only expectation of
pain decrease (day 1) and PS (day 1) reached the set p value
(Table 2). Then, multiple linear regression analysis was per-
formed using forced entry methods with pain intensity NRS
(day 8) as the dependent variable, and PS (day 1) and expec-
tation of pain decrease NRS (day 1) as independent variables.
The overall fit of the model was examined by using adjusted
R2 values (0.28) and leverage (0.11).
Patients with a high expectation of pain decrease NRS on
day 1 had a significantly lower pain intensity NRS (day 8)
(p = 0.001, partial correlation coefficient = 0.36). Those with a
low PS also had a significantly lower pain intensity NRS (day
8) (p = 0.001) (Table 2). The normality of the residuals of the
final model of multiple regression analysis was confirmed
using Kolmogorov-Smirnov test while independent variables
did not have normal distribution.
Pain intensity NRS (day 8) showed almost no correlation
with HADS total score on day 8 (r = 0.199).
Discussion
The results of this study show that patients with an expectation
for pain decrease NRS (day 1) had a significantly lower pain
intensity NRS (day 8). To our knowledge, this is the first
prospective study to examine the effect of an expectation of
a change in pain before morphine treatment on pain score
1 week later in opioid-naïve patients with various cancers
and PS. The results are consistent with findings in non-
cancer patients (whiplash injury, back pain) that pain score is
decreased in patients who expect pain improvement [12, 13].
To explain how a health expectation influences the outcome,
research on the mechanisms of placebo effects, of which expec-
tancy is generally considered to be the core mechanism, pro-
vides more well-grounded suggestions for the causal influence
of expectations on pain and other outcomes and for suggestions
to improve pain management by modulating expectations [27].
According to the response expectancy theory of Kirsch et al.,
response expectancy is defined as the anticipation of automatic,
subjective, and behavioral responses to particular situational
cues, and studies of the effects of placebos reveal that response
expectancies can produce lasting changes in pain [28].
An investigation of the effects of the expectation of pain
decrease NRS (day 1) indicated some effects on pain intensity
NRS (day 8) (partial correlation coefficient = 0.36) in the pres-
ent study. According to the meta-analyses on placebo and ex-
pectancy effects by Vase et al. [29], it was reported that mag-
nitudes of placebo analgesic effects were relatively low
(Hedges’ g = 0.15) in clinical analgesic trials (studies used only
placebo as a control condition) as compared to studies of pla-
cebo analgesia mechanisms (Hedges’ g = 0.95). Further com-
parison between acute and chronic pain indicated that magni-
tudes of placebo analgesic effects have been smaller (Hedges’
g = 0.33) in chronic pain than acute procedural pain (Hedges’
g = 0.67) in the recent meta-analyses by Peerdeman et al. [30].
Although the measures in previous studies were different and
unable to be simply compared due to the difference in study
designs, the expectation of pain decrease NRS (day 1) in the
present study might have a medium effect size with the partial
correlation coefficient. Interplay between symptoms (pain, oth-
er symptoms) and pessimistic illness perceptions, an increased
focus on bodily sensations, and inexpedient coping strategies
should also be investigated in future studies [12].
Our results suggest that pain relief in cancer patients can be
improved by increasing the patient’s expectation of pain im-
provement. However, these findings are from a prospective
observational study, and an interventional study is required
for further evaluation.
Patients with low PS also had lower pain intensity NRS
(day 8) (p = 0.001), which may be because most of low PS
patients were inpatients who received improved pain control
due to more frequent contact with medical staff.
This study has several limitations. First, 20–40% of
cancer patients have mental disorders that require therapy
[31]. Scores of 11 or greater for the anxiety or depression
scale of HADS are the cutoff for such disorders [32], and
67 of the 97 patients in the study (69%) had the anxiety or
depression scale of HADS score of ≥11, which is more
than in previous studies [31]. This may be because pa-
tients with cancer pain were selected as subjects.
Second, the patients were included by the decisions of
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attending physicians in two hospitals only and not contin-
uous sampling; we should consider selection bias, and the
results may not be generalizable to other institutions.
Third, disease duration, comorbidity, use of drugs other
than NSAIDs and opioids, and psychosocial factors in-
cluding education level and occupation were not exam-
ined. Finally, the possibility of response bias as a result
of using observer ratings and self-reported questionnaires
must be taken into consideration. Several studies have
shown that if we ask patients about their expectations of
treatment outcome, the expectation scores are very often
highly predictive for reports of treatment effectiveness
under the influence of biases traditionally termed leniency
and halo errors [33, 34]. We should consider this well-
known psychological effect. Considering response bias,
we attempted to prevent it from impacting our findings
in a negative manner; nurses who were not related to
our research handed the questionnaire to patients; howev-
er, it might be possible that some study results were due
to a response bias rather than the hypothesized effect.
Within these limitations, we conclude that cancer patients
with pain who expect to have relief from pain before pain
control treatment are more likely to have an actual improve-
ment of pain. For control of cancer pain, it may be helpful for
oncologists and palliative care doctors to develop their com-
munication skills. By improving the communication skills to
improve the doctor-patient relationship, the amount of re-
quired dose of analgesics can be reduced by the rise of
Bexpectations^ of a patient and the reduction of pain. It may
be possible to treat cancer patients of chemical coping
[20–22], which has recently become a problem.
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